While all information is believed to be reliable, it is not guaranteed by us to be accurate. is a wholly-owned subsidiary of Maynard Communication Limited. The content in this report or email is not provided to any individual with a view toward their individual circumstances. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. Please consult a licensed financial advisor before making any investment decision. No communication by our employees to you should be deemed as personalized financial advice.

We are not licensed under securities laws to address your particular financial situation. Nothing in this publication should be considered as personalized financial advice. In turn, these sensor readings could allow an implant to autonomously modulate and vary its power delivery to where it would be most effective. In addition, MedtronicВ previously saidВ it plans to submit to the FDA a responsive, closed-loop neuromodulation system by the end of this year-combining DTM with the ability to record evoked compound action potentials, or ECAPs.Д®CAP signals trace the simultaneous firing of bundles of stimulated nerve fibers within the spinal cord, to help measure the bodyвЂ™s instant response to therapy within a particular location. About 82% of patients implanted with a spinal cord stimulator will require at least one scan within five years of beginning treatment with the device, the company estimates.Д®lsewhere in MedtronicвЂ™s neuromodulation division, the company delivered clinical data last year showing that its pain treatment algorithm employing differential target multiplexed therapy-known as DTM, which modulates electrical pulses in sync with interactions among the bodyвЂ™s nerve cells-could deliver stronger, sustained relief after one year compared to conventional spinal cord stimulation.Д¬urrently, DTM is only available through the companyвЂ™s rechargeable Intellis platform, but Medtronic saidВ it plans to announce more information about rolling out the program to its entire spinal cord stimulator portfolio later this summer. In addition, the Vanta allows for full-body MRIs. This can adjust the intensity of stimulation based on whether they are lying down, sitting or standing up, which may shift the location of the spinal cord and its distance from the implantвЂ™s electrodes. The Vanta device also includes MedtronicвЂ™s AdaptiveStim technology that tracks the patientвЂ™s movement and body position with an internal accelerometer.

Meanwhile, Boston ScientificВ recently launched its Wavewriter Alpha product lineВ in the U.S.В andВ Europe, with four models including rechargeable and non-rechargeable versions-the latter delivering a device lifetime of just over five years with its typical settings. The Vanta follows AbbottвЂ™s Proclaim XR, approved by the agencyВ in 2019, which claims up to 10 years of battery power when programmed to its lowest doses. ItвЂ™s a leap ahead of older device models that might need surgical replacement every two to five years, and offers a pain treatment alternative to rechargeable implants-which, while much smaller and longer-lasting, do require weekly or monthly top-ups wirelessly through the skin. With properly optimized power delivery settings, the medtech giant says the Vanta system can last up to 11 years-or 10% longer than the companyвЂ™s last-generation neurostimulator, the PrimeAdvanced device, while also being 20% smaller. Medtronic scored FDA approval for its latest spinal cord stimulation implant for chronic pain, with a non-rechargeable device promising nearly double the battery life of previous hardware.

Gravity lab bangkok